Danish Medicines Council rejects Novartis breast cancer drug

During its May meeting, the Danish Medicines Councils has rejected breast cancer drug Piqray, which is developed by Novartis, and has partly reversed a prior rejection of acute myeloid leukemia (AML) treatment Xospata, developed by Astellas Pharma.

by albert rønning anderssen, translated by daniel pedersen

Published: 20.05.22 at 14:03

Yesterday, Novartis suffered a blow in Denmark.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

Ambu, Coloplast and GN helped by relaxation of China's covid policy

Protests in China have led to a relaxation in Covid-19 restrictions. | Foto: Thomas Peter

The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.

Sonova completes Hysound Group acquisition, strengthens presence in China

Arnd Kaldowski, CEO of Sonova | Foto: Sonova / Pr

The hearing aid giant now owns over 200 hearing clinics in China.

Extra data boosts Lundbeck's agitation case

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.